Sign in

BTCY on OTC

BIOTRICITY INC.

BIOTRICITY INC. is an American surgical and medical instruments and apparatus company.2 It is headquartered in Redwood City, United States.2 Its shares trade on OTC under the symbol BTCY.2

Price unavailable

Last updated Oct 21, 2026.

Overview

$16.0MRevenue, fiscal 20263
-$2.4MNet income, fiscal 20263

Compare with Profound Medical Corp., ALLURION TECHNOLOGIES, INC. or Vivos Therapeutics, Inc., or pick any stock.

  • TickerBTCY on OTC2
  • IndustrySurgical & Medical Instruments & Apparatus2
  • HeadquartersRedwood City, United States2
  • Incorporated inNV4
  • Business address203 Redwood Parkway, Suite 600, Redwood City, Ca 940654
  • Filer categoryNon-accelerated filer, Smaller reporting company4
  • Legal formCorporation2
  • LEI5493000L48S51ZYDK2602
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered address701 S CARSON ST STE 200, 89701 Carson City, United States2
  • Registered withBusiness Center (Secretary of State), E0450872012-52

See how the biggest companies compare on our leaderboards

We believe this approach reduces the risk associated with traditional medical device development and accelerates the path to revenue.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

80.9%Gross margin3
10.6%Operating margin3
-15.0%Net margin3
16.0%Revenue growth, 20263

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Technology Fees brought in 90% of the revenue BIOTRICITY INC. broke down this way in fiscal 2026.

  1. Technology Fees$14.4M390%up 15% from 2025
  2. Device Sales$1.6M310%up 30% from 2025
Products and services by year
Products and services20252026
Technology Fees$12.6M$14.4M
Device Sales$1.2M$1.6M

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Cost of revenue19¢$3.0M
  • Research and development17¢$2.8M
  • Selling, general and admin53¢$8.5M
  • Other costs11¢$1.7M

Out of $16.0M in revenue.3 The company lost money this year.

Financial statements

Revenue678910113$16.0M in 2026+3918% since 2019
0$5.0M$10.0M$15.0M$20.0M2019: $398.2K$398.2K20192020: $1.4M$1.4M2020+256%2021: $3.4M$3.4M2021+139%2022: $7.7M$7.7M2022+126%2023: $9.6M$9.6M2023+26%2024: $12.1M$12.1M2024+25%2025: $13.8M$13.8M2025+14%2026: $16.0M$16.0M2026+16%
Gross profit678910113$12.9M in 2026+21530% since 2019
0$5.0M$10.0M$15.0M2019: $59.9K$59.9K20192020: $485.8K$485.8K2020+711%2021: $1.3M$1.3M2021+162%2022: $4.6M$4.6M2022+259%2023: $5.4M$5.4M2023+19%2024: $8.4M$8.4M2024+54%2025: $10.6M$10.6M2025+26%2026: $12.9M$12.9M2026+23%
Operating income910113$1.7M in 2026
-$20.0M-$15.0M-$10.0M-$5.0M0$5.0M2022: -$16.7M-$16.7M20222023: -$15.4M-$15.4M2023−8%2024: -$8.8M-$8.8M2024−43%2025: -$2.4M-$2.4M2025−72%2026: $1.7M$1.7M2026
Net income678910113-$2.4M in 2026−72% since 2019
-$30.0M-$20.0M-$10.0M02019: -$8.6M-$8.6M20192020: -$11.1M-$11.1M2020+29%2021: -$15.5M-$15.5M2021+40%2022: -$29.1M-$29.1M2022+88%2023: -$18.7M-$18.7M2023−36%2024: -$14.1M-$14.1M2024−24%2025: -$8.4M-$8.4M2025−40%2026: -$2.4M-$2.4M2026−71%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2026-03-312025-03-31
REVENUE$16.0M$13.8M
Cost of Revenue$3.0M$3.2M
GROSS PROFIT$12.9M$10.6M
Selling, general and administrative expenses$8.5M$10.9M
Research and development expenses$2.8M$2.2M
TOTAL OPERATING EXPENSES$11.3M$13.0M
INCOME (LOSS) FROM OPERATIONS$1.7M-$2.4M
Other income/(expense) [Note 3]$160.0K-$78.6K
Interest expense-$3.4M-$3.3M
Gain/(Loss) upon convertible promissory notes conversion and redemption [Note 8]$19.8K-$137.9K
Accretion and amortization expenses-$745.9K-$1.9M
Change in fair value of derivative liabilities [Note 8]-$167.3K-$553.9K
NET LOSS BEFORE INCOME TAXES-$2.4M-$8.4M
NET LOSS BEFORE DIVIDENDS-$2.4M-$8.4M
Preferred Stock Dividends-$724.3K-$466.1K
Deemed Dividend-$3.1M
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS-$3.1M-$11.9M
Translation adjustment-$35.5K$113.4K
COMPREHENSIVE LOSS-$3.2M-$11.8M
LOSS PER SHARE, BASIC-$0.12-$0.56
LOSS PER SHARE, DILUTED-$0.12-$0.56
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC27.3M shares21.5M shares
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED27.3M shares21.5M shares

Compare BIOTRICITY INC. with another company

Corporate structure

BIOTRICITY INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of BIOTRICITY INC.

  • Ionic Ventures, LLC Filed SCHEDULE 13G/A on BIOTRICITY INC., latest Aug 14, 2026 (9 filings since Aug 8, 2024)
  • BIOTRICITY INC. Redwood City, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What BIOTRICITY INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$29.8K3 Mar 31, 2026$29.8K3 Mar 31, 20250%
Accumulated depreciation$26.1K3 Mar 31, 2026$20.2K3 Mar 31, 2025+29.5%
Property and equipment, net$3.6K3 Mar 31, 2026$9.6K3 Mar 31, 2025−62.0%
Operating-lease assets (leased space)$346.2K3 Mar 31, 2026$812.1K3 Mar 31, 2025−57.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$149.8K3 Mar 31, 2026$365.1K3 Mar 31, 2025−59.0%

Inventory

ItemLatestA year beforeChange
Inventory, total$1.3M3 Mar 31, 2026$1.6M3 Mar 31, 2025−13.8%
Finished goods$572.7K3 Mar 31, 2026$329.7K3 Mar 31, 2025+73.7%

Properties, in its own words

Our principal executive office is located in leased premises of approximately 8,300 square feet at 203 Redwood Shores Parkway, Suite 600, Redwood City, California. We believe that these facilities are adequate for our needs, including providing the space and infrastructure to accommodate our development work based on our current operating plan. We do not own any real estate.

Item 2 of the 10-K filed Jul 14, 2026.5

Leadership

Who has led BIOTRICITY INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Waqaas Al-Siddiq2019–2023

Chair

  1. Waqaas Al-Siddiq2019–2023

President

  1. Waqaas Al-Siddiq2020–2023

Chief financial officer

  1. John Ayanoglou2019–2023
20202025
Board members and other officers (7)

Former names

  • METASOLUTIONS, INC.Jan 27, 2015 to Jan 5, 20164

Timeline

  1. Sep 28, 20268-K Executive or director change24
  2. May 1, 20268-K Entered a material agreement; Unregistered sale of shares; Bylaws or fiscal year changed25
  3. Feb 18, 20268-K Results of operations26
  4. Nov 18, 20258-K Results of operations27
  5. Feb 24, 20258-K Results of operations28
  6. Nov 20, 20248-K Results of operations29
  7. Aug 16, 20248-K Shareholder vote30
  8. Aug 7, 20248-K Listing notice or transfer31
  9. Aug 1, 20248-K Listing notice or transfer32
  10. Jul 16, 20248-K Unregistered sale of shares; Other events33
  11. Jul 12, 20248-K Shareholder vote34
  12. Jun 24, 20248-K Entered a material agreement; Unregistered sale of shares35
  13. Aug 1, 2019New chief executive Waqaas Al-Siddiq becomes CEO15
  14. Aug 28, 2012Founded BIOTRICITY INC. is founded2

Calendar

When it reported results

  1. Feb 18, 2026Reported quarterly or annual results26
  2. Nov 18, 2025Reported quarterly or annual results27
  3. Feb 24, 2025Reported quarterly or annual results28
  4. Nov 20, 2024Reported quarterly or annual results29
  5. Aug 17, 2023Reported quarterly or annual results36
  6. Jul 5, 2023Reported quarterly or annual results37
  7. Nov 18, 2022Reported quarterly or annual results38
  8. Aug 17, 2022Reported quarterly or annual results39

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

127 filings to the SEC since October 2021: 7 annual reports, 16 quarterly reports, 41 major events, 9 insider forms, 9 large holders, 1 private raises, 44 other. The latest 20:

  1. Oct 7, 2026RW EDGAR
  2. Sep 28, 20268-K EDGAR
  3. Aug 19, 202610-Q EDGAR
  4. Aug 17, 2026NT 10-Q EDGAR
  5. Aug 14, 2026SCHEDULE 13G/A EDGAR
  6. Jul 14, 202610-K EDGAR
  7. Jun 29, 2026NT 10-K EDGAR
  8. Jun 16, 2026DEF 14C EDGAR
  9. May 29, 2026PRE 14C EDGAR
  10. May 12, 2026SCHEDULE 13G/A EDGAR
  11. May 1, 20268-K EDGAR
  12. Feb 18, 20268-K EDGAR
  13. Feb 11, 202610-Q EDGAR
  14. Feb 4, 2026SCHEDULE 13G/A EDGAR
  15. Dec 19, 2025S-1 EDGAR
  16. Nov 18, 20258-K EDGAR
  17. Nov 14, 2025SCHEDULE 13G/A EDGAR
  18. Nov 14, 202510-Q EDGAR
  19. Aug 14, 202510-Q EDGAR
  20. Aug 12, 2025SCHEDULE 13G/A EDGAR

The 127 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 0 buys and 3 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Oct 11, 2021Rosa David ADirectorSale3,318$3.05$10.1KForm 4
Oct 8, 2021Rosa David ADirectorSale9,481$3.20$30.3KForm 4
Oct 7, 2021Rosa David ADirectorSale17,228$3.08$53.1KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$1.0M 2024–2024
Money received by yearMoney received by year, 2024–2024: $1.0M in all. Private raises (Form D) $1.0M.$0$250K$500K$750K$1M2024 · Private raises (Form D): $1.0M2024
Figures by year
YearPrivate raises (Form D)Total
2024$1.0M$1.0M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Mar 25, 2024Raised $1 million in a private offering of equity41 Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Strengthening Families & Communities, LLC48,263$6.0K0.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How BIOTRICITY INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBIOTRICITY INC.1
  • CIK0001630113
  • Employer ID (EIN)30-09835315
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company5
  • Incorporated innevada5
  • Fiscal year endsMarch 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address203 Redwood Parkway, Suite 600, Redwood City, CA 940651
  • Phone(800) 590-41551
  • Shares outstanding19,914,003 as of Aug 19, 202614
  • Public float$13.5M as of Sep 30, 20255
  • AuditorSRCO Professional Corporation, Richmond Hill, Ontario, Canada PCAOB ID 5828; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceJan 27, 20151
  • Filings317 in all: 8-K (113), 10-Q (33), CORRESP (17), UPLOAD (16), S-1/A (13), 4 (12), 10-K (11), 3 (8)1
    All 38 form types

    424B3 (8), EFFECT (8), NT 10-Q (8), SCHEDULE 13G/A (7), 424B5 (6), NT 10-K (6), D (5), S-1 (5), S-3 (5), S-3/A (4), 10-Q/A (3), 8-K/A (3), DEF 14A (3), PRE 14A (3), 10-K/A (2), 10-KT (2), DEFA14A (2), RW (2), 25-NSE (1), 4/A (1), 8-A12B (1), 8-A12G (1), CERT (1), CT ORDER (1), D/A (1), DEF 14C (1), PRE 14C (1), SC 13D (1), SC 13G (1), SC 13G/A (1)

  • Latest filingsAnnual report (10-K) Jul 14, 2026
    Quarterly report (10-Q) Aug 19, 2026
    Proxy statement (DEF 14A) Aug 5, 2024
    Latest 8-K (8-K) Sep 28, 2026

Risk factors and legal proceedings

The risks BIOTRICITY INC. names in Item 1A of its 10-K filed Jul 14, 2026: 55 risks under these headings, as written.5

  • Risks Related to Our Business
  • Natural disasters and other events beyond our control could materially adversely affect us.
  • We have a limited operating history upon which investors can rely to evaluate our future prospects.
  • We have not had a long history of producing revenues and we cannot predict when we will achieve sustained profitability.
  • We may not meet our product development and commercialization milestones.
  • We have entered into a Credit Agreement pursuant to which we have granted the lender a security interest in all of our assets including our intellectual property and if we default on our obligations in the Credit Agreement the lender could foreclose on our assets.
  • Our business is dependent upon physicians utilizing our solution when prescribing cardiac monitoring; if we fail to continue to be successful in convincing physicians in utilizing our solution, our revenue could fail to grow and could decrease.
  • We are subject to extensive governmental regulations relating to the manufacturing, labeling and marketing of our products.
  • If our customers are not able to both obtain and maintain adequate levels of third-party reimbursement for services using our products, it would have a material adverse effect on our business.
  • Our customers may experience difficulty in obtaining reimbursement for our services from commercial payors that consider our technology to be experimental and investigational, which would adversely affect our revenue and operating results.
  • Reimbursement by Medicare is highly regulated and subject to change; our failure to comply with applicable regulations, could decrease our expected revenue and may subject us to penalties or have an adverse impact on our business.
  • Consolidation of commercial payors could result in payors eliminating coverage of mobile cardiac monitoring solutions or reducing reimbursement rates.
The other 44 risks
  • Product defects could adversely affect the results of our operations.
  • Interruptions or delays in telecommunications systems or in the data services provided to us by cellular communication providers or the loss of our wireless or data services could impair the delivery of our cardiac monitoring services.
  • We could be exposed to significant liability claims if we are unable to obtain insurance at acceptable costs and adequate levels or otherwise protect ourselves against potential product liability claims.
  • We require additional capital to support our present business plan and our anticipated business growth, and such capital may not be available on acceptable terms, or at all, which would adversely affect our ability to operate.
  • We cannot predict our future capital needs and we may not be able to secure additional financing.
  • The results of our research and development efforts are uncertain and there can be no assurance of the continued commercial success of our products.
  • If we fail to retain certain of our key personnel and attract and retain additional qualified personnel, we might not be able to pursue our growth strategy.
  • Executive and legislative actions, or legal proceedings that seek to amend or impede the implementation of the Affordable Care Act, as well as future efforts to repeal, replace or further modify the Affordable Care Act may adversely affect our business, financial condition and results of operations.
  • We will not be profitable unless we can demonstrate that our products can be manufactured at low prices.
  • Significant developments or changes in national laws or policies to protect or promote domestic interests and/or address foreign competition can have an adverse effect on our business and financial statements.
  • We are vulnerable to changes in political and economic conditions, including the effects of tariffs and/or international trade wars and disruptions to remittances.
  • New or increased tariffs or other trade restrictions could have a material adverse effect on our business, financial condition, results of operations and cash flows.
  • If we or our suppliers fail to achieve or maintain regulatory approval of manufacturing facilities, our growth could be limited, and our business could be harmed.
  • Our dependence on a limited number of suppliers may prevent us from delivering our devices on a timely basis.
  • Our operations in international markets involve inherent risks that we may not be able to control.
  • Our existing and future levels of indebtedness could adversely affect our financial health, ability to obtain financing in the future, ability to react to changes in our business and ability to fulfill our obligations under such indebtedness.
  • Our auditors have indicated doubt about our ability to continue as a going concern.
  • Risks Related to Our Industry
  • The industry in which we operate is highly competitive and subject to rapid technological change. If our competitors are better able to develop and market products that are safer, more effective, less costly, easier to use, or are otherwise more attractive, we may be unable to compete effectively with other companies.
  • We face competition from other medical device companies that focus on similar markets.
  • Unsuccessful clinical or other trials or procedures relating to products under development could have a material adverse effect on our prospects.
  • Intellectual property litigation and infringement claims could cause us to incur significant expenses or prevent us from selling certain of our products.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • If we are unable to protect our proprietary rights, or if we infringe on the proprietary rights of others, our competitiveness and business prospects may be materially damaged.
  • Dependence on our proprietary rights and failing to protect such rights or to be successful in litigation related to such rights may result in our payment of significant monetary damages or impact offerings in our product portfolios.
  • Enforcement of federal and state laws regarding privacy and security of patient information may adversely affect our business, financial condition or operations.
  • We may become subject, directly or indirectly, to federal and state health care fraud and abuse laws and regulations and if we are unable to fully comply with such laws, the Company could face substantial penalties.
  • We may be subject to federal and state false claims laws which impose substantial penalties.
  • Changes in the health care industry or tort reform could reduce the number of arrhythmia monitoring solutions ordered by physicians, which could result in a decline in the demand for our planned solutions, pricing pressure and decreased revenue.
  • Risks Related to Our Securities and Other Risks
  • There is a limited existing market for our common stock and we do not know if a more liquid market for our common stock will develop to provide you with adequate liquidity.
  • The market price of our common stock may be volatile.
  • There may be a significant number of shares of common stock eligible for sale, which could depress the market price of such stock.
  • Our largest stockholder will substantially influence our Company for the foreseeable future, including the outcome of matters requiring shareholder approval and such control may prevent you and other stockholders from influencing significant corporate decisions and may result in conflicts of interest that could cause the Company’s stock price to decline.
  • Failure to maintain effective internal control over our financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 (“Sarbanes-Oxley Act”) could cause our financial reports to be inaccurate.
  • Our issuance of additional common stock or preferred stock may cause our common stock price to decline, which may negatively impact your investment.
  • Anti-takeover provisions in the Company’s charter and bylaws may prevent or frustrate attempts by stockholders to change the board of directors or current management and could make a third-party acquisition of the Company difficult.
  • Our common stock could become subject to the SEC’s penny stock rules and accordingly, broker-dealers may experience difficulty in completing customer transactions and trading activity in our securities may be adversely affected.
  • We have not paid dividends in the past and do not expect to pay dividends in the future, and any return on investment may be limited to the value of our stock.
  • Risks Related to Intellectual Property
  • We have no utility patent protection, and have only limited design patent protection and rely on unregistered copyright and trade secret protection, if we are unable to obtain and maintain patent protection for our products, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our existing products and any products we may develop, and our technology may be adversely affected.
  • Any failure to obtain or maintain sufficient intellectual property protection with respect to our current and planned products could have a material adverse effect on our business, financial condition, and results of operations.
  • We may not be able to protect our intellectual property and proprietary rights throughout the world.
  • We may become involved in intellectual property litigation either due to claims by others that we are infringing their intellectual property rights or due to our own assertions that others are infringing upon our intellectual property rights.
  • We have not done any investigation of and thus cannot provide assurance that our products or methods do not infringe the patents or other intellectual property rights of third parties.
  • We may also be subject to claims that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.
  • If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. None identified.

Legal proceedings

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm business.

We are not currently a party in any material legal proceeding where we are defendants, or governmental regulatory proceeding.

The opening of Item 3, Legal Proceedings.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41